SRDX News and Press, Surmodics Inc. From 11/17/23

2023-11-17 15:15:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that 36-month data from its TRANSCEND clinical trial was presented by Dr. Peter A. Schneider at the 50 th Annual VEITH Symposium in New York, N...

Sundance™ Sirolimus Drug-Coated Balloon exhibits excellent safety profile Primary patency maintained at 24 months in 71.4% of per protocol analysis population Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the h...

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that management will participate in the 35th Annual Piper Sandler Healthcare Conference, which is being held at the Lotte New York Palace in New Yo...

2023-11-10 10:06:06 ET Surmodics, Inc. (SRDX) Q4 2023 Earnings Conference Call November 08, 2023 08:00 AM ET Company Participants Gary Maharaj - President & Chief Executive Officer Tim Arens - Chief Financial Officer Conference Call Participants Brook...

2023-11-08 07:48:58 ET More on Surmodics Sizing Up Surmodics, Inc. Seeking Alpha’s Quant Rating on Surmodics Historical earnings data for Surmodics Financial information for Surmodics For further details see: Surmodics Non-GAAP EPS of $0.53...

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its fourth quarter and fiscal year ended September 30, 2023, and introduced its financial guidance for the fiscal year ending ...

2023-11-08 06:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...

Surmodics Inc. (SRDX) is expected to report $0.16 for Q4 2023